
Ikonisys
Providing fully-automated slide handling, slide scanning, and real-time image capture and analysis for microscopy.
Date | Investors | Amount | Round |
---|---|---|---|
N/A | €0.0 | round | |
investor investor investor investor | €0.0 | round | |
investor | €0.0 | round | |
N/A | €0.0 | round | |
N/A | €0.0 | round | |
N/A | €0.0 | round | |
investor | €0.0 | round | |
investor | €0.0 | round | |
investor | €0.0 | round | |
N/A | €0.0 | round | |
* | N/A | €200k | Private Placement VC |
Total Funding | 000k |







Related Content
Ikonisys Inc. operates in the healthcare diagnostics sector, focusing on the development and marketing of advanced cancer diagnostic tools. The company specializes in cell-based diagnostics, utilizing its proprietary Digital Microscope technology to deliver highly accurate and reliable detection of rare cancer cells. Ikonisys collaborates with Empire Genomics to enhance its FISH probes, optimizing results for various cancer detection tests. The company's products are designed to meet the stringent requirements of healthcare providers and the needs of patients, ensuring high-quality medical diagnostics. Ikonisys serves healthcare professionals and institutions, providing them with cutting-edge tools for cancer diagnosis. The business model revolves around the sale and distribution of its diagnostic products, generating revenue through product sales and strategic collaborations. Led by CEO Mario Crovetto, who has extensive experience in the healthcare sector, Ikonisys is committed to maintaining an effective Quality Management System, ensuring that all employees adhere to high standards in their work.
Keywords: cancer diagnostics, digital microscopy, rare cell detection, healthcare, FISH probes, medical diagnostics, cell-based, healthcare providers, strategic collaboration, quality management.
Tech stack
Investments by Ikonisys
Edit